Skip to content

Endometrial Biopsy Prior to IVF in Those Patients With Prior Implantation Failure

EVAULATION OF IMPLANTATION AND PREGNANCY AFTER ENDOMETRIAL INJURY VIA ENDOMETRIAL PIPELLE BIOPSY IN THE CYCLE PRIOR TO IVF: A RANDOMIZED, SINGLE-BLINDED, CONTROLLED TRIAL.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01800513
Acronym
EMBX/IVF
Enrollment
254
Registered
2013-02-27
Start date
2013-02-28
Completion date
2015-12-31
Last updated
2013-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Implantation Failure, Infertility

Keywords

Implantation Failure, In-vitro Fertilization, Infertility, Endometrial Biopsy

Brief summary

This proposed research is a single center, prospective, single-blinded, randomized controlled trial, designed to evaluate IVF pregnancy outcomes following endometrial injury in 254 patients with implantation failure. Patients will be identified during their work-up and treatment at Shady Grove Fertility Reproductive Science Center. Only Shady Grove patients are eligible for the study. The investigators hypothesize in patients with one or more previous failed day 5 blastocyst transfers, injury to the endometrium via endometrial biopsy will improve clinical pregnancy outcomes compared to controls.

Detailed description

Despite advances in assisted reproductive technologies; implantation failure in patients undergoing in-vitro fertilization (IVF) is frequent. Unfortunately, few treatments exist except for the use of a gestational carrier. There have been a number of recent clinical studies demonstrating that local injury to the endometrium results in improved clinical pregnancy outcomes for patients with a history of implantation failure. However, not all studies have shown a beneficial effect, and those demonstrating benefit have been limited by small sample sizes, and considerable heterogeneity in the procedures and populations evaluated. A recent meta-analysis synthesized the available data concluded that a large, prospective, well-designed randomized trial is desperately needed to definitively assess this new possible treatment. If these preliminary findings from previous trials are confirmed, this practice could be applied in the clinical setting to help patients suffering from repeated implantation failures.

Interventions

PROCEDUREEndometrial Biopsy
PROCEDURESham Procedure

Sponsors

Shady Grove Fertility Reproductive Science Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 37 Years
Healthy volunteers
No

Inclusion criteria

* Women age 18-37 * One or more previous implantation failures with autologous fresh or frozen blastocyst transfer * Undergoing fresh autologous IVF cycle * No other current uterine (i.e.: uterine fibroids, polyps), hematologic, or genetic causes for infertility and implantation failure * One or more good quality blastocyst(s) available for transfer

Exclusion criteria

* Those unable to comprehend the investigational nature of the proposed study * Positive pregnancy test * Possible causes for impaired implantation (systemic disease, endometriosis, ultrasound evidence of current hydrosalpinx, uterine polyps, uterine myomas (fibroids), uterine cavity malformations or Asherman's syndrome) * Poor responders, defined as FSH \>12 on day 3 or less than 4 follicles on a previous IVF cycle * BMI \>30 or \<18

Design outcomes

Primary

MeasureTime frame
The primary outcome measurement in this study is clinical pregnancy rate, which is defined as identification of a fetal heart beat on ultrasound.8-10 weeks after embryo transfer

Secondary

MeasureTime frame
implantation rate8-10 weeks after embryo transfer
miscarriage rate2 years
multiple gestation rateat delivery
endometrial thickness during stimulationduring stimulation
Live Birth rate10 months after IVF cycle

Countries

United States

Contacts

Primary ContactErin F Wolff, M.D.
wolffe@mail.nih.gov

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026